End In Sight For Ovarian Cancer Patients With $5.5B+ J&J Deal
The $5.5 billion global deal over talc ovarian cancer allows women to move past recent court setbacks requiring them to provide experts who can show a causal link between their disease...To view the full article, register now.
Already a subscriber? Click here to view full article